***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: The therapeutic effects , safety and side-effects of clocapramine and sulpiride were evaluated in 52 hospitalized chronic schizophrenic patients using a single-blind method during an 8-week trial period . While the final global improvement rating showed clocapramine to be superior to sulpiride , the differences were not statistically significant . The time course of the total psychiatric rating scales ( PRS ) showed a progressive decline during treatment for both drugs , and at the end of treatment clocapramine proved significantly lower in total PRS than did sulpiride . In the improvement of psychotic symptoms , clocapramine seemed to be superior to sulpiride with respect to motor retardation , delusion , hallucination or disturbance of self-consciousness , social isolation or withdrawal , and recreation or work . Side-effects appeared more frequently with clocapramine than with sulpiride , but abnormal laboratory-test results appeared less in clocapramine-treated patients than in sulpiride-treated ones . Neither side-effects nor abnormal laboratory-test results induced by the two drugs were severe enough to terminate administration . Clocapramine is concluded to have a more favourable effect on negative symptoms , as well as on some positive symptoms of chronic schizophrenia , than sulpiride Previous clinical trials have clearly shown the superiority of olanzapine to haloperidol in the improvement of extrapyramidal symptoms ( EPS ) in schizophrenic patients . The primary purpose of this study was to compare EPS profiles in Japanese schizophrenic patients treated with an atypical antipsychotic , olanzapine , or a typical antipsychotic , haloperidol  , as measured by the Drug-Induced Extrapyramidal Symptoms Scale ( DIEPSS ) . The DIEPSS , which consists of eight individual parameters and one global assessment ( overall severity ) , was used to evaluate 182 patients enrolled in this 8-week study . The primary safety analysis was maximum change ( that could be either a decrease or increase ) from baseline in DIEPSS total score . Secondary analyses included change from baseline to maximum in DIEPSS total score , change from baseline to endpoint ( LOCF ) in DIEPSS total score , and the rank sum of the maximum change ( that could be either a decrease or increase ) from baseline in the DIEPSS individual items . Incidence of treatment-emergent EPS adverse events using the DIEPSS scale was also analyzed . The olanzapine group showed statistically significant superiority to the haloperidol group on the primary analysis ( p<0.001 ) . Secondary analyses also demonstrated olanzapine 's superiority in DIEPSS total , parkinsonism , akathisia and overall severity scores ( all p < or = 0.014 ) . Categorical analysis of treatment-emergent akathisia and parkinsonism syndromes at endpoint showed improvement in the olanzapine group but worsening in the haloperidol group . The results from this study suggest that olanzapine , as in Caucasian population s , is a safe treatment in Japanese patients chronically ill with schizophrenia 
    Output:
    
On the Positive and Negative Syndrome Scale , mosapramine ’s positive subscale scores were superior to those of the other pooled antipsychotics ( st and ard mean of difference = −0.22 ) ; however , on that same scale , there were no significant differences in total scores , negative scores , general subscale scores , response rates , or the discontinuation rates between mosapramine and the other pooled antipsychotics .
Furthermore , the incidences of extrapyramidal symptoms and of hyperprolactinemia were significantly greater with mosapramine than with the other pooled antipsychotics .
Conclusion The pharmacological profiles of carpipramine and clocapramine , which are classified as SGAs , were similar to those of first-generation antipsychotics because there were no significant differences in efficacy and safety outcomes .
However , mosapramine was associated with a greater risk of extrapyramidal symptoms and hyperprolactinemia than the other SGAs were , although it may be beneficial for the improvement of positive symptoms